- medaffairs@deqaseharesearch.ae
- +971 58 665 3631
Excerpt from from the published article “Successes and Challenges in Clinical Trial Recruitment: The Experience of a New Study Team”
Recruitment and Retention in Global Clinical Research
Recruitment and retention of participants are central to the success of global clinical trials. Major multinational studies frequently experience delays or fail due to under-enrollment and poor retention, highlighting the necessity for sophisticated, globalized recruitment services.
Recruitment is Critical to The Success of Global Clinical Trials:
Direct Impact on Timelines and ROI: 86% of international clinical trials fail to meet recruitment targets within planned timelines, causing delays in drug development and increased operational costs.
Data Power and Validity: Underpowered studies due to inadequate enrollment or high dropout rates weaken results and may limit regulatory approval.
Global Diversity and Real-World Relevance: Trials lacking geographic and demographic diversity produce less generalizable findings, which can impede both regulatory success and health equity.
Why Global Recruitment Partners Are Essential
- Access to Diverse Populations: Global recruitment partners enable targeting across regions and underserved groups, strengthening trial diversity and scientific impact.
- Expedited Enrollment: Leveraging broad international networks and advanced technology, they accelerate participant enrollment and minimize costly delays.
- Regulatory Expertise: They provide crucial guidance on navigating complex, region-specific regulatory requirements in multi-country clinical research.
- Multimodal Outreach and Retention: Their expertise in digital, community, and provider engagement drives better patient participation and delivers culturally attuned support for improved retention.
Are you ready to accelerate your clinical research? Partnering with Deqa Wa Seha’s global recruitment services is the key to faster, more diverse, and highly impactful trials. By leveraging extensive networks, advanced digital tools, and in-depth local insights, we enable expedited enrollment, seamless regulatory navigation, and improved participant retention across the globe.
Collaborating with specialized global recruitment partners helps reduce costly delays, broaden patient diversity, and bring therapies to market more quickly. Now is the time to invest in strategic, scalable, and innovative solutions that drive clinical trial success.
Let’s unlock the future of clinical research together—connect with Deqa Wa Seha’s experts today and transform your trial outcomes. (Man Hung et al., 2024).
Reference:
Man Hung, A. Mohajeri, K. Almpani, G. Carberry, J. F. Wisniewski, K. Janes, … & F. W. Licari. (2024). Successes and challenges in clinical trial recruitment: The experience of a new study team.
Medical Sciences (Basel), 12(3), 39.
#ClinicalResearchAdvancement #InnovateClinicalResearch #PatientRecruitment #ClinicalTrialInnovation #TrialRetention #ResearchOpportunities
Evidence, publications, and perspective from our clinical research team.
Deqa Wa Seha contributes to the global evidence base through peer-reviewed publications, congress research, and white papers. Explore our published work in oncology, real-world evidence, and health economics — alongside practical perspectives on running trials across global markets.
The depth of evidence and thinking behind how we operate.
Our leadership has authored and led research presented at major international congresses and published in respected peer-reviewed journals — spanning hepatocellular carcinoma registries, accelerated approval pathways, and cross-market burden-of-disease studies. This section brings that body of work together with our own white papers, so sponsors and partners can see the depth of evidence and thinking behind how we operate.
Peer-reviewed articles, congress abstracts & posters.
A curated list of authored publications. Items 1–11 are authored by Dr. Yvanka Gilliam; items 12–13 are AHCC08 Asia-Pacific registry publications whose operational architecture she led. Each entry links to the abstract, poster, or article on the publisher’s primary source.
Authored Publications
01
Differences in presentation and management patterns in patients with hepatocellular carcinoma (HCC) between China and Singapore: initial data from the HCC Registry in Asia.
Chow PKH, …, Gilliam YM, et al.
02
Differences and similarities in presentation and management patterns in patients with hepatocellular carcinoma (HCC) across Hong Kong, Singapore and Thailand.
Chow PKH, …, Gilliam Y, et al.
03
Differences and similarities in presentation and management patterns in patients with hepatocellular carcinoma (HCC) across Hong Kong, Singapore and Thailand.
Chow PKH, …, Gilliam Y, et al.
04
The challenges and unmet needs in the management of hepatocellular carcinoma (HCC) patients and burden of advanced HCC across Hong Kong, Singapore and Thailand.
Yen C, …, Gilliam Y, et al.
05
APAC overview of the accelerated approval pathways: applications in lung cancer.
Johnson I, Chou B, Grillo V, Sevilla M, Singh SS, Gilliam Y.
06
Uncovering the hidden burden of depression: a country comparison.
Ken-Opurum J, Fukuda T, Chen Y, Gilliam Y, Stankus A.
07
Rates of COPD diagnosis and health outcomes in at-risk populations: an insight to the diagnosis of COPD.
Chen Y, Gilliam Y, Singh SS, Jung S, Fang H.
08
Vaccination rates among the general adult population and high-risk groups in EU, US, Japan, South Korea and Taiwan.
Gilliam Y (lead author), Teoh C, Singh SS, Chen Y, Grillo V.
09
Hepatitis B and C: differences in diagnosis and treatment.
Gilliam Y (lead author), Singh SS, Chen Y, Kim J, Fang H.
10
Comparison of quality of life and burden of lower back pain among patients with and without a diagnosis in Korea, Taiwan, Japan and USA.
Chen Y, Singh SS, Fang H, Jung S, Gilliam Y, Grillo V.
11
Potential patient leakage from underdiagnosis of EGFR exon20 insertions in non-small cell lung cancer based on real-world testing behavior in Japan and Korea.
Delgerekh N, …, Gilliam Y, et al.
AHCC08 Registry Team Publications
The two publications below emerged from the AHCC08 Asia-Pacific Hepatocellular Carcinoma registry, whose operational architecture Dr. Gilliam led across her tenure at IQVIA Asia-Pacific and Kantar Health. She is not in the byline, but the operational leadership is verified.
12
Differences in presentation and management patterns in patients with hepatocellular carcinoma (HCC): data from HCC registry in Asia.
Chow PKH, et al.
13
Real-world data on the diagnosis, treatment, and management of hepatocellular carcinoma in the Asia-Pacific: the INSIGHT Study. 2,533 patients, 33 sites, 9 countries.
Sim YK, et al.
Practical perspectives on running clinical research across global markets.
Each paper is available as a downloadable PDF. We publish a card here only once the final PDF and title are confirmed — so what you see is what you can rely on.
White paper title — to be confirmed
Short abstract describing the paper's focus and key takeaways. This card will publish once the final PDF is confirmed.
White paper title — to be confirmed
Short abstract describing the paper's focus and key takeaways. This card will publish once the final PDF is confirmed.
White paper title — to be confirmed
Short abstract describing the paper's focus and key takeaways. This card will publish once the final PDF is confirmed.
Want the evidence behind our work?
Whether you are evaluating a partner or building a study, our published research and white papers show how we think and how we deliver. Reach out to discuss your program.
- medaffairs@deqaseharesearch.ae
- +971 58 665 3631
- Unit 823 Al Irshad Street, Al Hisn, Abu Dhabi, UAE
From Insight to Execution
The thinking you see here is the same thinking we apply to live studies. Our insights aren’t abstract commentary — they come from running trials at the site level, every day.
Turn a topic into action
- See a challenge that mirrors your own program? Let's talk about how we would handle it for you.
- We translate lessons from real studies into practical plans for yours.
- Every conversation starts with your specific trial, not a generic pitch.
If a topic here maps to a problem in your program, bring it to us and we will show you how we would put it into practice.